TCV-309 | CAS#131311-25-6 | PAF inhibitor

MedKoo Cat#: 526944 | Name: TCV-309

Description:

WARNING: This product is for research use only, not for human or veterinary use.

TCV-309 is a platelet activating factor (PAF) inhibitor. TCV-309 attenuates the priming effects of bronchoalveolar macrophages in cerulein-induced pancreatitis rats. TCV-309 reduces graft PMN infiltration and enhances early function of 24-hour-preserved rat kidneys with long warm ischemia. TCV-309 inhibits leukocyte accumulation and protects against splanchnic artery occlusion shock.

Chemical Structure

TCV-309

CAS#131311-25-6

Theoretical Analysis

MedKoo Cat#: 526944

Name: TCV-309

CAS#: 131311-25-6

Chemical Formula: C30H34BrN5O7

Exact Mass:

Molecular Weight: 656.53

Elemental Analysis: C, 54.88; H, 5.22; Br, 12.17; N, 10.67; O, 17.06

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

TCV-309; TCV 309; TCV309.

IUPAC/Chemical Name

3-bromo-5-((3-oxo-3-((2-((1,2,3,4-tetrahydroisoquinoline-2-carbonyl)oxy)ethyl)amino)propyl)(phenyl)carbamoyl)-1-propylpyridin-1-ium nitrate

InChi Key

DVGLBKDNVHDMTD-UHFFFAOYSA-O

InChi Code

InChI=1S/C30H33BrN4O4.NO3/c1-2-15-33-20-25(19-26(31)22-33)29(37)35(27-10-4-3-5-11-27)17-13-28(36)32-14-18-39-30(38)34-16-12-23-8-6-7-9-24(23)21-34;2-1(3)4/h3-11,19-20,22H,2,12-18,21H2,1H3;/q;-1/p+1

SMILES Code

CCC[N+]1=CC(C(N(CCC(NCCOC(N2CC3=C(C=CC=C3)CC2)=O)=O)C4=CC=CC=C4)=O)=CC(Br)=C1.[O-][N+]([O-])=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 656.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Poeze M, Froon AH, Ramsay G, Buurman WA, Greve JW. Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group. Shock. 2000 Oct;14(4):421-8. PubMed PMID: 11049104. 2: Yamaguchi Y, Matsumura F, Liang J, Okabe K, Matsuda T, Ohshiro H, Ishihara K, Akizuki E, Yamada S, Ogawa M. Platelet-activating factor antagonist (TCV-309) attenuates the priming effects of bronchoalveolar macrophages in cerulein-induced pancreatitis rats. Pancreas. 1999 May;18(4):355-63. PubMed PMID: 10231840. 3: Qayumi AK, English JE, Duncan S, Ansley DM, Pearson B, Nikbakht-Sangari M, Sammartino C, Fradet G. Extended lung preservation with platelet-activating factor-antagonist TCV-309 in combination with prostaglandin E1. J Heart Lung Transplant. 1997 Sep;16(9):946-55. PubMed PMID: 9322146. 4: Yin M, Buurman WA, Daemen JW, Kootstra G. The PAF antagonist TCV-309 reduces graft PMN infiltration and enhances early function of 24-hour-preserved rat kidneys with long warm ischemia. Transplantation. 1996 May 27;61(10):1443-6. PubMed PMID: 8633367. 5: Froon AM, Greve JW, Buurman WA, van der Linden CJ, Langemeijer HJ, Ulrich C, Bourgeois M. Treatment with the platelet-activating factor antagonist TCV-309 in patients with severe systemic inflammatory response syndrome: a prospective, multi-center, double-blind, randomized phase II trial. Shock. 1996 May;5(5):313-9. PubMed PMID: 9156785. 6: Yin M, Kurvers HA, Buurman WA, Tangelder GJ, Tiebosch AT, Daemen JH, Kootstra G. Platelet-activating factor antagonist TCV-309 protects rat kidneys against ischemia-reperfusion injury. Transplant Proc. 1995 Oct;27(5):2844-6. PubMed PMID: 7482939. 7: Okano S, Tagawa M, Urakawa N. Effect of platelet activating factor antagonist (TCV-309) on lung injury in dogs with experimentally endotoxin-induced shock. J Vet Med Sci. 1995 Aug;57(4):751-3. PubMed PMID: 8519912. 8: Okano S, Tagawa M, Urakawa N. Effect of TCV-309, a novel platelet activating factor antagonist, on hemodynamics in dogs with endotoxin-induced shock. J Vet Med Sci. 1995 Apr;57(2):385-7. PubMed PMID: 7492672. 9: Yin M, Kurvers HA, Buurman WA, Tangelder GJ, Booster MH, Daemen JH, Kondracki S, Kootstra G. Beneficial effect of platelet-activating factor antagonist TCV-309 on renal ischemia-reperfusion injury. Transplant Proc. 1995 Feb;27(1):774-6. PubMed PMID: 7879180. 10: Ide S, Kawahara K, Takahashi T, Sasaki N, Shingu H, Nagayasu T, Yamamoto S, Tagawa T, Tomita M. Donor administration of PAF antagonist (TCV-309) enhances lung preservation. Transplant Proc. 1995 Feb;27(1):570-3. PubMed PMID: 7879103. 11: Canale P, Squadrito F, Altavilla D, Ioculano M, Zingarelli B, Campo GM, Urna G, Sardella A, Squadrito G, Caputi AP. TCV-309, a novel platelet activating factor antagonist, inhibits leukocyte accumulation and protects against splanchnic artery occlusion shock. Agents Actions. 1994 Oct;42(3-4):128-34. PubMed PMID: 7879698. 12: Kawamura M, Kitayoshi T, Terashita Z, Fujiwara S, Takatani M, Nishikawa K. Effects of TCV-309, a novel PAF antagonist, on circulatory shock and hematological abnormality induced by endotoxin in dogs. J Lipid Mediat Cell Signal. 1994 May;9(3):255-65. PubMed PMID: 7921785. 13: Tamura K, Kimura Y, Tamura T, Kitashiro S, Izuoka T, Tsuji H, Iwasaka T, Inada M. The effect of platelet-activating-factor antagonist TCV-309 on arrhythmias and functional recovery during myocardial reperfusion. Coron Artery Dis. 1994 Mar;5(3):267-73. PubMed PMID: 8199742. 14: Kuipers B, van der Poll T, Levi M, van Deventer SJ, ten Cate H, Imai Y, Hack CE, ten Cate JW. Platelet-activating factor antagonist TCV-309 attenuates the induction of the cytokine network in experimental endotoxemia in chimpanzees. J Immunol. 1994 Mar 1;152(5):2438-46. PubMed PMID: 8133055. 15: Yamanaka S, Iwao H, Yukimura T, Kim S, Miura K. Effect of the platelet-activating factor antagonist, TCV-309, and the cyclo-oxygenase inhibitor, ibuprofen, on the haemodynamic changes in canine experimental endotoxic shock. Br J Pharmacol. 1993 Dec;110(4):1501-7. PubMed PMID: 8306093; PubMed Central PMCID: PMC2175868. 16: Katoh S, Toyama J, Kodama I, Koike A, Abe T. Role of platelet activating factor in ischaemia-reperfusion injury of isolated rabbit hearts: protective effect of a specific platelet activating factor antagonist, TCV-309. Cardiovasc Res. 1993 Aug;27(8):1430-4. PubMed PMID: 8221795. 17: Kawahara K, Tagawa T, Takahashi T, Akamine S, Nakamura A, Yamamoto S, Muraoka S, Tomita M. The effect of the platelet-activating factor inhibitor TCV-309 on reperfusion injury in a canine model of ischemic lung. Transplantation. 1993 Jun;55(6):1438-9. PubMed PMID: 8516834. 18: Kawamura M, Terashita Z, Imura Y, Shino A, Nishikawa K. Inhibitory effect of TCV-309, a novel platelet activating factor (PAF) antagonist, on endotoxin-induced disseminated intravascular coagulation in rats: possible role of PAF in tissue factor generation. Thromb Res. 1993 May 15;70(4):281-93. PubMed PMID: 8332959. 19: Tomaszewska R, Dembiński A, Warzecha Z, Banaś M, Konturek SJ, Stachura J. Platelet activating factor (PAF) inhibitor (TCV-309) reduces caerulein- and PAF-induced pancreatitis. A morphologic and functional study in the rat. J Physiol Pharmacol. 1992 Dec;43(4):345-52. PubMed PMID: 1294265. 20: Terashita Z, Takatani M, Nishikawa K. Pharmacological profile of TCV-309--a potent PAF antagonist. J Lipid Mediat. 1992 Jun-Jul;5(2):183-5. PubMed PMID: 1445598.